Literature DB >> 7586337

Low serum cholesterol and mortality. Which is the cause and which is the effect?

C Iribarren1, D M Reed, R Chen, K Yano, J H Dwyer.   

Abstract

BACKGROUND: Many studies have reported an association between a low or lowered blood total cholesterol (TC) level and subsequent nonatherosclerotic disease incidence or death. The question of whether low TC is a true risk factor or alternatively a consequence of occult disease at the time of TC measurement remains unsettled. To shed new light onto this problem, we analyzed TC change over a 6- year period (from exam 1 in 1965 through 1968 to exam 3 in 1971 through 1974) in relation to subsequent 16-year mortality in a cohort of Japanese American men. METHODS AND
RESULTS: The study was based on 5941 men 45 to 68 years of age without prior history of coronary heart disease, stroke, cancer, or gastrointestinal-liver disease at exam 1 who also participated in exam 3 of the Honolulu Heart Program. The association of TC change with mortality end points was investigated with two different approaches (continuous and categorical TC change) with standard survival analysis techniques. Falling TC level was accompanied by a subsequent increased risk of death caused by some cancers (hemopoietic, esophageal, and prostate), noncardiovascular noncancer causes (particularly liver disease), and all causes. The risk-factor-adjusted rate of all-cause mortality was 30% higher (relative risk, 1.30; 95% CI, 1.06 to 1.59) among persons with a decline from middle (180 to 239 mg/dL) to low (< 180 mg/dL) TC than in persons remaining at a stable middle level. By contrast, there was no significant increase in all-cause mortality risk among cohort men with stable low TC levels. Nonillness mortality (deaths caused by trauma and suicide) was not related to either TC change or the average of TC levels in exams 1 and 3.
CONCLUSIONS: These results add strength to the reverse-causality proposition that catabolic diseases cause TC to decrease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586337     DOI: 10.1161/01.cir.92.9.2396

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

Review 1.  Optimal low-density lipoprotein levels: evidence from epidemiology and clinical trials.

Authors:  Josh Todd; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

2.  Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease.

Authors:  Xuemei Huang; Honglei Chen; William C Miller; Richard B Mailman; Jennifer L Woodard; Peter C Chen; Dong Xiang; Richard W Murrow; Yi-Zhe Wang; Charles Poole
Journal:  Mov Disord       Date:  2007-02-15       Impact factor: 10.338

Review 3.  Management of lipids in the elderly.

Authors:  A Winder
Journal:  J R Soc Med       Date:  1998-04       Impact factor: 5.344

4.  Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Silvia Rollefstad; Eirik Ikdahl; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Eric L Matteson; Tore K Kvien; Karen Douglas; Aamer Sandoo; Elke Arts; Solveig Wållberg-Jonsson; Lena Innala; George Karpouzas; Patrick H Dessein; Linda Tsang; Hani El-Gabalawy; Carol Hitchon; Virginia Pascual Ramos; Irazú Contreras Yáñez; Petros P Sfikakis; Evangelia Zampeli; Miguel A Gonzalez-Gay; Alfonso Corrales; Mart van de Laar; Harald E Vonkeman; Inger Meek; Anne Grete Semb
Journal:  Ann Rheum Dis       Date:  2017-09-06       Impact factor: 19.103

5.  A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer.

Authors:  Gemma Llaverias; Christiane Danilo; Yu Wang; Agnes K Witkiewicz; Kristin Daumer; Michael P Lisanti; Philippe G Frank
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

6.  Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Veronique L Roger; Patrick D Fitz-Gibbon; Terry M Therneau; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

Review 7.  Comparative tolerability of the HMG-CoA reductase inhibitors.

Authors:  J A Farmer; G Torre-Amione
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

8.  Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles.

Authors:  G T Lesser; M S Beeri; J Schmeidler; D P Purohit; V Haroutunian
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

9.  Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.

Authors:  J Wardle; J Armitage; R Collins; K Wallendszus; A Keech; A Lawson
Journal:  BMJ       Date:  1996-07-13

10.  Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study.

Authors:  Ali Abbasi; Petronella E Deetman; Eva Corpeleijn; Ron T Gansevoort; Rijk O B Gans; Hans L Hillege; Pim van der Harst; Ronald P Stolk; Gerjan Navis; Behrooz Z Alizadeh; Stephan J L Bakker
Journal:  Diabetes       Date:  2014-11-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.